Porphyrin-lipid nanovesicles (PLN) have been developed with intrinsic capabilities as activatable multimodal photonic contrast agents. Radiolabeling of PLN encapsulating drugs could eventually be able to provide quantitative in vivo information for diagnosing and treating diseases. In this study, we developed 99m Tc-labeled porphyrin-lipid nanovesicles ( 99m Tc-PLN) as a cargo-encapsulated formulation without significant impact on liposome integrity and encapsulation stability. 50 mM calcein was encapsulated into PLN by probe sonication. The size of the PLN was about 150 nm. The PLN were then reacted with 99m Tc using SnCl 2 dissolved in 1 mM HCl as a reducing agent and incubated for 10 min at 22 C. The radiolabeling efficiency and stability of 99m Tc-PLN were evaluated by instant thin-layer chromatography and lowpressure liquid chromatography (LPLC).
Introduction
Activatable drug release systems have attracted active research interests due to their possibility of maximizing drug efficacy and disease treatment, and improving imaging resolution by delivering drugs and imaging modality agents in right times and places (Ellis et al., 2012; Goga et al., 2011; Guo et al., 2013; Lee et al., 2013a; Snyder et al., 2003) . Activatable porphyrin-lipid nanovesicles (PLN) were developed based on porphyrin's innate properties that can be excited by 658 nm laser and its fluorescent property (Jin et al., 2013; Lovell et al., 2011; Ng et al., 2013) . When a 658-nm laser excites porphyrin nanovesicles, porphyrin nanovesicles can release photothermal energy and release drugs depending on the nanovesicle formulation (Carter et al., 2014) . Thus, it provides the potentials not only as multimodal photonic contrast agents but also as triggering drug-release carriers. In this study, radiolabeling of PLN-encapsulating drugs can provide critical in vivo quantitative information on these PLN for diagnosing and treating disease.
Liposomes can be used for applications such as drug delivery and imaging due to their size-controllable selfassembly nature (Malam et al., 2009; Torchilin, 2005) .
Lipid nanovesicles are especially useful platforms due to their high drug loading and manufacturing versatility among current clinical trials' nanoparticles (Chang & Yeh, 2012; Malam et al., 2009; Torchilin, 2005) . However, drugs in the liposome can be released at unspecific times due to the difficulties in controlling drug encapsulation and drug release. Porphyrin-lipid nanovesicles can be a potential system to overcome this shortcoming by activatable drug release. In vivo tracking of the PLN can get information on the distribution and uptake of the PLN at target sites and its potential efficacy in treatment (Liu et al., 2012) . Radiolabeling of liposome nanovesicles with 99m Tc would allow in vivo tracking by SPECT (Weers et al., 2009) .
So far, radiolabeling of the PLN-encapsulating drugs has not been fully studied. Liposome-encapsulated drugs have different biodistributions and toxicities as compared with ''free'' drugs (Yan et al., 2008) . Thus, in this study, we investigated the radiolabeling of a model drug loaded PLN with 99m Tc. Specifically, we evaluated the stability of drug encapsulation and integrity of the 99m Tc-PLN. Radiolabeling of PLN-encapsulating drugs can provide in vivo quantitative information on PLN for diagnosing and treating diseases. We used the 99m Tc surface-radiolabeling method due to its mild labeling condition, which can potentially apply for the labeling of the final pharmaceutical product and allow encapsulated drugs to remain inert inside the PLN (Lee et al., 2013b) . Stable 99m Tc labeling of PLN is ideal because 99m Tc (physical half life ¼ 6 h) is inexpensive and readily available. Gamma scintigraphy (SPECT) can be used to evaluate their potential clinical application studies such as lung treatments (Conway, 2012; Elbayoumi & Torchilin, 2006; Phillips, 1999; Richardson et al., 1979; Weers et al., 2009) . In this study, we optimized PLN composition for stable drug encapsulation and 99m Tc labeling parameters to yield a high labeling efficiency without a significant impact on the liposome integrity and drug encapsulation. The 99m Tc-PLN were investigated by size exclusion low-pressure liquid chromatography (LPLC) that was recently developed for cholesterol-rich liposome analysis (Lee et al., 2013b) . With this analytical method, both 99m Tc binding and release from the liposome outer leaflet, model of encapsulated drug leakage, and the detachment of fluorescent lipid can be evaluated simultaneously.
Materials and methods
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless specified otherwise. Pyropheophorbide-a-lipid (C 57 H 79 N 5 PO 9 , MW¼ 1012.3 g/mole) was provided by Lovell's research group (Lovell et al., 2011) . All other lipids were purchased from Avanti Polar Lipids (Alabaster, AL), including dipalmitoylphosphatidyl-choline (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000).
Porphyrin-lipid nanoparticle preparation
Porphyrin-lipid nanovesicles were prepared by probe sonication. Briefly, a lipid film (total 5 mg per vial) was formed by removing chloroform solvent under nitrogen at room temperature using either porphyrin lipid:cholesterol (CH): PEG ¼ 45:50:5 molar ratio or porphyrin lipid: CH ¼ 50:50 molar ratio formulation. Residual chloroform was removed by placing the films overnight in a lyophilizer. To encapsulate calcein as a model drug, a lipid film was reconstituted in a self-quenched concentration of calcein (50 mM, 1 mL). The PLN were eluted through a size-exclusion gel chromatography column (sepharose CL 4B, pre-equilibrated with pH 7.0 saline buffer) to remove free calcein. The presence of PLN in the column fractions was analyzed by the measurement of entrapped calcein.
Radiolabeling of PLN
The PLN (0.4 mL in 0.9% NaCl) were radiolabeled using sodium pertechnetate Na + [ 99m TcO À 4 ] as described previously (Farr et al., 1985; Koizumi et al., 1992; Weers et al., 2009 Tc generator from Lantheus Medical Imaging, Inc., North Billerica, MA) was added to a sterile vial containing PLN (0.4 mL at 50 mM calcein) and the contents were shaken for approximately 30 s. A volume of 0.02 mL of 2 mM SnCl 2 (Lot no. 452335) solution prepared in SnCl 2 dissolved in 1 mM HCl as a reducing agent for 10 min at 22 C, filtered through a 0.22-mm-sterilizing filter (MillexGV filter unit, Millipore, Billerica, MA) was then added into the vial. The vial was gently mixed for approximately 30 s and incubated at room temperature for 10 min. An aliquot of known volume was withdrawn for the determination of the specific activity (mCi/mg) of the radiolabeled PLN. The specific radioactivity concentration was 5.3 ± 0.5 mCi/mL (n ¼ 3). A further aliquot of known volume was withdrawn to determine the radiochemical purity. The 99m Tc-PLN were assessed to evaluate its radiolabeling efficiency and stability with ITLC and LPLC.
PLN characterization
PLN's size and size distribution were determined by dynamic light scattering (DLS) measurements using a Malvern instrument (NANO ZS, Malvern Instruments, Campbell, CA). The Z-average particle size was measured in triplicate. The integrity of the radiolabeled PLN was determined by several analytical methods. The samples were assessed by size exclusion LPLC equipped with a size exclusion Sepharose CL 6B column (25 Â 300 mm, GE Healthcare (El Paso, TX), 1.5% NaCl, pH 6.8; 0.8 mL/min) (modified for pressure pump use), an UV monitor, a fluorescent monitor, and an on-line flow radioactivity detector (Bioscan Inc., Washington, DC) (Lee et al., 2013b) . The radiochemical purity of 99m Tc-PLN was also evaluated by ascending ITLC (Gelman Sciences, Inc., Ann Arbor, MI) using 100% acetone as the solvent phase (Arulsudar et al., 2003) . Calcein entrapment efficiency was determined by a fluorescent intensity change at 495 nm excitation (Ex)/515 nm emission (Em), using a fluorescence microplate reader (SpectraMax M2, Molecular Devices, Silicon Valley, CA) after adding the detergent Triton X-100 (TX100, 0.02% final concentration). The drug encapsulation efficiency was calculated using the following formula: F t /F 0 where F t is the fully dequenched drug fluorescence intensity after the addition of TX100 and F 0 is the fluorescence intensity of drug before the addition of TX100.
Results and discussion

PLN formation
In this study, we used cholesterol rich formulation (porphyrin lipid:cholesterol (CH): PEG ¼ 45:50:5 or porphyrin lipid: CH ¼ 50:50) (for all the presented data except a long-term drug encapsulation study, porphyrin lipid:cholesterol (CH): PEG ¼ 45:50:5 formulation was used due to its stable formulation in vivo). LPLC analysis was performed to test the stability of the PLN and drug encapsulation. The elution results of PLN-encapsulating calcein demonstrated the clear separation of free calcein from the calcein-encapsulated PLN (Figure 1a) . PLN with cholesterol-rich composition that was eluted through a size-exclusion gel chromatography column (sepharose CL 4B) showed a dark green color and was collected in the early stage successfully. The particle size and size distribution of PLN were analyzed with dynamic light scattering. The size was determined to be 141.6 ± 1.9 nm (P.I.50.16) after the LPLC size exclusion column (before size exclusion column 134.4 ± 1.8 nm (P.I.50.29), which indicates nano-size PLN formations (Figure 1b ) (for porphyrin lipid: CH ¼ 50:50, the size was 96.9 ± 0.3 nm (P.I.50.20) before size exclusion column). The characteristic UV-Vis peak of PLN due to its porphyrin structure was also analyzed before and after 99m Tc radiolabeling. UV-Vis spectra of the PLN indicate that the porphyrin's structure of the PLN remained inert in the nanoparticles (note that the 99m Tc-labeled PLN have the same spectrum) (Figure 1c ). The LPLC method was used to analyze cholesterol-rich PLN, which is an optimal analytical tool for PLN of this size range. The LPLC results showed that the liposomal peaks were detected by a UV-Vis monitor set at 485 nm and 680 nm, also by fluorescent monitor set at 420 nm Ex/680 nm Em. At 485 nm, strong calcein and porphyrin absorbance could be detected at the same time. At 680 nm, only strong porphyrin absorbance could be detected. At 420 nm Ex/680 nm Em, only strong porphyrin fluorescence could be detected. Interestingly, all three peaks overlapped each other, and all the peaks were different from free calcein (Figure 2 and see also Supporting information Figure S1 ), which indicates calcein had been successfully encapsulated. To check liposome integrity, the stability test by Triton X-100, known as a liposome-destabilizing surfactant, was performed. After Triton X-100 addition to the PLN solution (10 mL:100 mL), the LPLC analysis showed that the PLN were destabilized. The fluorescent detection of free calcein at 485 nm Ex/515 nm Em clearly demonstrated calcein encapsulation (Supporting information Figure S1 ). The drug encapsulation was also evaluated by a 96-well fluorescent reader. Upon the addition of Triton X-100, the fluorescent signal increased rapidly (Figure 3) . These LPLC and fluorescence microplate reader's data strongly support that calcein was stably encapsulated by the PLN.
We also studied long-term drug leakage rates of PLN by the fraction of drug release as a function of time, R(x),
where x is the day, and F(initial) and F(final) are the fluorescence intensity before and after adding the Triton X-100 (Wang et al., 2006) (Figure 4 ). Lower R(x) value indicated that encapsulated drug did not leak out for a longer time, suggesting that cholesterol-rich PLN are a stable liposome nanoparticle. These results demonstrated that PLN have a long-term stability like CTAT/SDBS equilibrium vesicles. Porphyrin lipid has only one hydrophobic tail. The addition of cholesterol increases the hydrophobic volume and critical packing parameter of PLN. As a result, the cholesterol formulation improves thermo-dynamical liposome stability of the PLN. 
Radiolabeling chemistry and analysis of PLN
The 99m Tc labeling of PLN was efficient in the presence of stannous chloride (80 mM) in 0.91 mM ascorbic acid or 1 mM HCl, producing 99m Tc-PLN with a high labeling yield: 96.1 ± 2.8% (n ¼ 3) and 88.2 ± 3.4% (n ¼ 3), when determined by ITLC and LPLC, respectively. The LPLC profiles traced by UV, fluorescence, and online radioactivity monitor indicate that the 99m Tc-radiolabeled PLN had a mono-disperse peak (between 10 and 20 min) at the same elution time of control PLN ( Figure 5 ). The peak shape and retention time of these peaks were identical to those of the original unlabeled PLN, indicating that the 99m Tc-labeling condition did not change the size of PLN. This LPLC analysis also demonstrated that the integrity of PLN was maintained during 99m Tc-radiolabeling process. This finding indicates that encapsulated calcein remained inert inside the liposome and the PLN structure was not disrupted by the Tc-PLN, and the drug encapsulation maintenance detection traced by UV, fluorescence, and online radioactivity monitors. (Lee et al., 2013a) . This LPLC system equipped with multisignal detectors has been shown in this study as a very useful analysis for the determination of liposome integrity and drug encapsulation.
After radiolabeling, the drug encapsulation was evaluated by a 96-well fluorescent reader. Triton X-100 was added to Tc-PLN after 24 h storage at 4 C was the same as that of 99m Tc-PLN immediately after radiolabeling, indicating that the 99m Tc binding to PLN was very stable. The elution peak of 99m Tc pertechnetate was observed in the later elution time (about 45-50 min) (less than 20%). The 99m Tc-binding stability against Triton X-100 was also evaluated after 24 h storage at 4 C (Figure 8 ). The elution peak of 99 m Tc pertechnetate was observed (about 40%). Interestingly, calcein leakage (less than 10%) was not greater than that from the control PLN (about 30%) after Triton X-100 treatment. The main monodisperse peak of 99m Tc-PLN was still observed. Considering that the addition of Triton X-100 into the PLN solution can induce calcein leakage according to the fluorescent study (Figure 6 ), it suggests that Triton X-100 makes the PLN leaky while leaving their size unaltered at the condition of Triton X-100 to PLN solution ¼ 10 mL:100 mL. The size measurement of the PLN after adding Triton Â by DLS confirmed this suggestion. However, it cannot exclude the possibility of further micellization by adding more Triton X-100.
There are two potential binding sites of 99m Tc to the PLN surface after reducing the oxidation state of 99m Tc +7 to 99m Tc +4 : one possible site is complexation with the phosphate moieties on the surface of the PLN (Lee et al., 2013b; Phillips, 1999) , and the second site is that 99m Tc +4 can possibly bind to a porphyrin functional group (Spagnul et al., 2013 ) (see Supporting information Figure S2 Tc-radiolabeled PLN by a 96-well fluorescence microplate. After the addition of Triton X-100, the fluorescent intensity increase was monitored, demonstrating that the drug encapsulation remained inert. Tc-binding stability of 99m Tc-PLN against Triton X-100 addition after 24 h storage at 4 C. About 40%, 99m Tc detachment was observed and the main monodisperse peak of 99m Tc-PLN remained inert. not change the calcein encapsulation properties of PLN. Thus, 99m Tc-PLN will be able to be used for tracking the in vivo biodistribution of PLN by SPECT imaging.
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